Lexaria Bioscience

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs encompassing fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

DehydraTECHTM CBD-Beverage Demonstrates 93.4% Potency One Year After Production Lexaria's Nanoemulsification Processing Technique Ensures Content Uniformity and Homogeneity of CBD Distribution Without Need for Physical Mixing KELOWNA, BC / ACCESSWIRE / March 24, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announced positive results from its extended stability testing, which has reported unparalleled stability for bottled CBD-containing beverages prepared using its technology. Lexaria's patented DehydraTECHTM CBD (cannabidiol) nanoemulsification formulation and processing techniques are responsible for the tested beverages maintaining their CBD content which was verified at 93.4% of target potency one year after production and also evidenced excellent microbial purity over this period.

Lexaria Technology Generates Positive Stability Testing for World-Class Ready-to-Drink CBD Beverages

Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX) (OTCMKTS:LXR) announced Tuesday extensive progress in two of the four planned antiviral drug studies in its 2021 applied research and development (R&D) program. “It's been a very productive start into 2021 with a total of seven studies across our various research programs currently underway,” said Lexaria CEO Chris Bunka in a statement.

Lexaria Bioscience reports progress in two antiviral drug studies in its 2021 applied R&D program

Two of the four planned studies progressing to examine DehydraTECH™ with antivirals targeting SARS-CoV-2 / COVID-19 . KELOWNA, BC / ACCESSWIRE / March 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces extensive progress in two of the four planned antiviral drug studies in its 2021 applied research and development (R&D) program.

Lexaria's Antiviral Drug Evaluation Program Progressing

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) has updated investors on the progress of assessing its DehydraTECH CBD technology in treating high blood pressure, noting that all five of its planned studies for this year are now underway. Three human clinical trials and two animal research studies are in progress.

Lexaria Bioscience updates on progress of its DehydraTECH CBD studies to treat high blood pressure

Five studies underway to examine DehydraTECHTM CBD for Hypertension. KELOWNA, BC / ACCESSWIRE / March 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces extensive progress in five studies focused on the performance of DehydraTECHTM CBD as a treatment for hypertension.

Rapid Progress in Hypertension Studies by Lexaria

Lexaria recently expanded its hypertension R&D program evaluating effectiveness of DehydraTECH-processed CBD to three human clinical studies and two animal studies KELOWNA, BC / ACCESSWIRE / March 11, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that CEO Chris Bunka is presenting and will be available to meet with investors and analysts on a one-on-one basis at the 33rd Annual Virtual ROTH Conference to be held on March 15-17, 2021. Mr. Bunka will provide an overview of the Company, including its DehydraTECH™ drug delivery technology that improves the way active pharmaceutical ingredients enter the bloodstream.

Lexaria to Present and Meet with Investors One-on-One at the 33rd Annual Virtual ROTH Conference on March 15-17, 2021

Novel drug delivery platform DehydraTECH masks unwanted tastes, improves onset speed, increases bioavailability of active ingredients Cannabis is the current focus, but company eyeing massive markets such as nicotine and painkillers Currently working on using DehydraTECH to deliver antiviral drugs and help in the global fight against coronavirus What Lexaria Bioscience does: Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) is a Canadian company with a patented technology that promises to change the way drugs are delivered into the body. The Kelowna, British Columbia-based company has developed and markets DehydraTECH, which masks unwanted tastes, improves onset speed and increases the bioavailability of active pharmaceutical ingredients in a simple and cost-effective platform.

Lexaria Bioscience's DehydraTECH drug delivery system can unlock more effective CBD — and may even help fight COVID-19

VANCOUVER, BC, Feb. 16, 2021 /PRNewswire/ - Lexaria Bioscience's (NASDAQ: LEXX) (CSE: LEXX) drug delivery technology, DehydraTECHTM improves the "bioavailability" of pharmaceutical ingredients. "Bioavailability is the rate and extent to which a therapeutically active substance enters...

Lexaria Bioscience (LEXX.NASDAQ) (LEXX.CSE) $11 million financing supports R&D program targeting high blood pressure and SARS-CoV-2 infection

Lexaria Bioscience Corp (NASDAQ:LEXX) (CSE:LXX) is expanding its applied research and development (R&D) program in 2021 with a particular focus on DehydraTECH-enabled CBD for hypertension, the company announced Thursday.  The company's hypertension program now consists of five planned studies, three of which were previously announced on February 1 (HYPER-A21-1, HYPER-A21-2, and HYPER-H21-1).

Lexaria Bioscience expands DehydraTECH CBD hypertension program with two new human trials; updates for others

New York, New York--(Newsfile Corp. - February 9, 2021) - PCG Digital - Chris Bunka is a happy man. As CEO of Lexaria Bioscience (NASDAQ: LEXX) since 2006, he's battled to legitimize cannabinoids as a mainstream medical solution. This week, his dream is coming true. Jazz Pharmaceuticals, a major player with $2.3 billion in annual revenue, has entered the fray.The deal went down on Wednesday, February 3rd. Jazz completed an acquisition of GW Pharmaceuticals,...

Lexaria Outlook is Promising After Jazz Acquisition of GW

The stock price of Lexaria Bioscience Corp (NASDAQ: LEXX) is trading at over 50% today. This is why it happened.

LEXX Stock Price Increases Over 50%: Why It Happened

Phoenix, Arizona--(Newsfile Corp. - January 28, 2021) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (NASDAQ: LEXX) (CSE: LXX) ("the Company"), a company with the proprietary drug delivery technology, DehydraTECH™, which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream. CEO of the Company, Chris Bunka, joined Stock Day host Everett Jolly. Jolly began the interview by congratulating Bunka on the Company's Nasdaq Capital Market uplisting, which was announced on January 12th, 2021....

Lexaria Bioscience Corp. Discusses $11 Million Public Offering and 2021 Goals with The Stock Day Podcast

KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors.

Lexaria Appoints New Board Member

KELOWNA, BC / ACCESSWIRE / January 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced the closing of its previously announced underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance.

Lexaria Bioscience Corp. Announces Closing of $11 Million Public Offering with Full Exercise of Underwriter Option to Purchase Additional Shares and Warrants

KELOWNA, BC / ACCESSWIRE / January 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company") today announced that its common stock and warrants will begin trading on the Nasdaq Capital Market on January 12, 2021, under the symbols "LEXX" and "LEXXW," respectively. Lexaria also announced the pricing of an underwritten public offering (the "Offering") of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$).

Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering

News for Lexaria Bioscience Stock (LEXX)